Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies

被引：0
|
作者：
Ronald Goldwater
Azra Hussaini
Bill Bosch
Paul Nemeth
机构：
[1] PAREXEL Early Phase Clinical Unit,
[2] Churchill Pharmaceuticals LLC,undefined
来源：
Clinical Pharmacokinetics | 2017年 / 56卷
关键词：
Meloxicam; Abiraterone; Healthy Male Subject; Abiraterone Acetate; Dose Proportionality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：803 / 813
页数：10
相关论文
共 50 条
  • [41] Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers
    Jain, Jay Prakash
    Leong, F. Joel
    Chen, Lan
    Kalluri, Sampath
    Koradia, Vishal
    Stein, Daniel S.
    Wolf, Marie-Christine
    Sunkara, Gangadhar
    Kota, Jagannath
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (09)
  • [42] Comparison of the Pharmacokinetics of Pitavastatin by Formulation and Ethnic GroupAn Open-Label, Single-Dose, Two-Way Crossover Pharmacokinetic Study in Healthy Caucasian and Japanese Men
    Steve Warrington
    Shunji Nagakawa
    Neil Hounslow
    Clinical Drug Investigation, 2011, 31 : 735 - 743
  • [43] Comparison of the Pharmacokinetics of Pitavastatin by Formulation and Ethnic Group An Open-Label, Single-Dose, Two-Way Crossover Pharmacokinetic Study in Healthy Caucasian and Japanese Men
    Warrington, Steve
    Nagakawa, Shunji
    Hounslow, Neil
    CLINICAL DRUG INVESTIGATION, 2011, 31 (10) : 735 - 743
  • [44] PHARMACOKINETIC COMPARISON OF AN ORALLY SOLUBLE FILM FORMULATION WITH A FILM COATED TABLET FORMULATION OF SILDENAFIL IN HEALTHY KOREAN SUBJECTS: A RANDOMIZED, OPEN-LABEL, SINGLE DOSE, CROSS-OVER, 2 PART CLINICAL TRIAL
    Roh, H.
    Son, H.
    Lee, D.
    Park, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S104 - S104
  • [45] Relative Bioavailability of Tizanidine Hydrochloride Capsule Formulation Compared with Capsule Contents Administered in Applesauce: A Single-Dose, Open-Label, Randomized, Two-Way, Crossover Study in Fasted Healthy Adult Subjects
    Henney, Herbert R., III
    Fitzpatrick, Anthony
    Stewart, Johnston
    Runyan, Jacob D.
    CLINICAL THERAPEUTICS, 2008, 30 (12) : 2263 - 2271
  • [46] Bioequivalence Study of Two Oral Methocarbamol Formulations in Healthy Subjects Under Fasting Conditions: A Randomized, Open-Label, Crossover Clinical Trial
    Ascaso-del-Rio, Ana
    Camargo-Mamani, Paola
    Gilaberte, Inmaculada
    Diez-Hochleitner, Monica
    Laredo-Velasco, Leonor
    Iglesias-Hernangomez, Teresa
    Salas-Butron, Maria Rosario
    Caballero, Laura Galan
    Diaz-Rengifo, Ivan Alejandro
    Perez-Ingidua, Carla
    Vargas-Castrillon, Emilio
    Portoles-Perez, Antonio
    PHARMACEUTICALS, 2025, 18 (03)
  • [47] A randomized, open-label, crossover study evaluating bioequivalence of two N-acetylcysteine 2% oral solution formulations in healthy subjects
    Donath, Frank
    Armogida, Marianna
    Shneyer, Lucy
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2018, 56 (09) : 417 - 425
  • [48] Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects
    Feifei Sun
    Yanping Liu
    Ting Li
    Pingping Lin
    Xin Jiang
    Xin Li
    Chenjing Wang
    Xiaomeng Gao
    Yaping Ma
    Yao Fu
    Yu Cao
    BMC Pharmacology and Toxicology, 24
  • [49] Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects
    Sun, Feifei
    Liu, Yanping
    Li, Ting
    Lin, Pingping
    Jiang, Xin
    Li, Xin
    Wang, Chenjing
    Gao, Xiaomeng
    Ma, Yaping
    Fu, Yao
    Cao, Yu
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [50] Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study
    Hsyu, Poe-Hirr
    Pignataro, Daniela Soriano
    Matschke, Kyle
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2018, 7 (04): : 373 - 381
12345